Formulation development and evaluation of medroxyprogesterone acetate injectable suspension
Abstract
The aim of the present work is to develop sustained release parenteral drug delivery system of contraceptive drug i., e medroxyprogesterone acetate. The formulation was prepared by sterile combining of API and excipient powders by rapid stirring method. Different excipients used in the formulation are PEG 3350, Poloxamer -188, Polysorbate-80, Benzyl alcohol and Sodium chloride. The prepared parenteral suspension was evaluated for all official parameters like sedimentation volume, measurement of zeta potential, pH, viscosity, osmolality, dissolution, assay, particle size determination, and stability studies. The dissolution profile was found to be more when compared with the innovator formulation. Stability studies were also conducted at 25ºC / 60% RH and 40ºC / 75% RH conditions up to 3M.All the parameters evaluated are within the specified limits.
Keywords: Medroxy progesterone acetate, PEG 3350, Poloxamer-188, injectable suspension.
Downloads
References
2. Aungst B. J, Intestinal permeation enhancers, Journal of Pharmaceutical Sciences, 2000; 89(4):428-442.
3. Lawrence M. J, Microemulsion-based media as novel drug delivery systems, Advanced Drug Delivery Reviews, 2000; 45(1): 89-121.
4. Patel CA, Keraliya R, A review: Parenteral depot drug delivery system, Journal of Drug Delivery Research, 2014; 3(1):1-10.
5. Parrott E L, Pharmaceutical technology: fundamental pharmaceutics, Burgness Publishing Company; 1970.
6. Cundy T, Farqubar CM, Cornish J, Reid IR, Short-term effects of high dose oral medroxy progesterone acetate on bone density in premenopausal women, Journal of Clinical Endocrinology and Metabolism, 1995; 81(3):1014-1017.
7. Chaurasia G, A review on pharmaceutical preformulation studies in formulation and development of new drug molecules, International Journal of Pharmaceutical Sciences and Research, 2016; 7(6):2313-2320.
8. Alam. A, Alka Ahuja, Sanjula Baboota, S. K. Gidwani, J. Ali, Formulation and evaluation of pharmaceutically equivalent parenteral depot suspension of methyl prednisolone acetate, Indian Journal of Pharmaceutical Sciences, 2009; 71(1):30-34.
9. William P. Forrest, Kevin G. Reuter, Vivek Shah, Irina Kazakevich, Michael Heslinga, Siddhi Dudhat, Sanjaykumar Patel, Claudia Neri, Yun Mao, USP Apparatus 4: A Valuable In Vitro Tool to Enable Formulation Development of Long-Acting Parenteral (LAP) Nanosuspension Formulations of Poorly Water-Soluble Compounds, AAPS PharmSciTech, 2017; 19(1):413-424.
10. Raymond C.R., Paul J.S., Marian E.Q. Handbook of Pharmaceutical excipients. Sixth edition. U.K.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).